Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nabi Biopharmaceuticals, a biopharmaceutical company engaged in the development of products in the areas of nicotine addiction and infectious diseases, has received two patents for key components of PentaStaph, the company's next-generations Staphylococcus aureus vaccine.
Subscribe to our email newsletter
The US Patent and Trademark office has issued a patent for the exclusive use of a vaccine comprised of the two most prevalent surface antigens in Staphylococcus aureus – capsular polysaccharides (CPS) Types 5 and 8 – for the prevention of infections in immune-compromised populations through September 2022.
Additionally, the European Patent Office has issued a patent that provides composition-of-matter protection in the EU through September 2016 for vaccines containing the surface polysaccharide component Type 336 which complements the already granted US patent for this same antigen.
Nabi also has pending applications for two additional toxoid antigens that were filed in 2007 and, if awarded, will provide composition and method of use claims through 2027. These vaccine components are currently undergoing pre-clinical toxicology testing to enable initiation of Phase I clinical trials in early 2009.
Raafat Fahim, president and CEO of Nabi Biopharmaceuticals, said: These additional patents represent a significant step in advancing the strategic value inherent in our gram-positive program, specifically in the area of healthcare-associated S aureus infections. Based on the results of the first pivotal clinical study of Nabi’s conjugate bivalent S aureus vaccine, we believe we can target Types 5 and 8 CPS and help protect against S aureus infections in dialysis patients.
And, our Phase I trial to evaluate the safety and immune response of the Type 336 antigen demonstrated that the vaccine was immunogenic and well-tolerated. These three antigens are an integral part of our next-generation vaccine PentaStaph, a five-component vaccine that we believe will provide comprehensive protection against the most clinically significant S aureus infections known today.